Cargando…

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

BACKGROUND: We evaluated bevacizumab with metronomic etoposide among recurrent malignant glioma patients in a phase 2, open-label trial. METHODS: A total of59 patients, including 27 with glioblastoma (GBM) and 32 with grade 3 malignant glioma, received 10 mg kg(−1) bevacizumab biweekly and 50 mg m(−...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reardon, D A, Desjardins, A, Vredenburgh, J J, Gururangan, S, Sampson, J H, Sathornsumetee, S, McLendon, R E, Herndon, J E, Marcello, J E, Norfleet, J, Friedman, A H, Bigner, D D, Friedman, H S
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2795427/ https://www.ncbi.nlm.nih.gov/pubmed/19920819 http://dx.doi.org/10.1038/sj.bjc.6605412

Ejemplares similares

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
por: Reardon, D A, et al.
Publicado: (2012)

A Pilot Study of IL-2Rα Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma
por: Sampson, John H., et al.
Publicado: (2012)

Tetanus toxoid and CCL3 improve DC vaccines in mice and glioblastoma patients
por: Mitchell, Duane A., et al.
Publicado: (2015)

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
por: Lou, Emil, et al.
Publicado: (2013)

A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab
por: Affronti, Mary Lou, et al.
Publicado: (2016)

The genetic landscape of anaplastic astrocytoma
por: Killela, Patrick J., et al.
Publicado: (2013)

Treatment of Recurrent Intracranial Hemangiopericytoma with SRC-Related Tyrosine Kinase Targeted Therapy: A Case Report
por: Peters, Katherine B., et al.
Publicado: (2010)

Single‐institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice
por: Desjardins, Annick, et al.
Publicado: (2019)

Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma
por: Affronti, Mary Lou, et al.
Publicado: (2018)

A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer
por: Kelley, R K, et al.
Publicado: (2013)

Current available therapies and future directions in the treatment of malignant gliomas
por: Desjardins, Annick, et al.
Publicado: (2009)

A Novel Method for Volumetric MRI Response Assessment of Enhancing Brain Tumors
por: Kanaly, Charles W., et al.
Publicado: (2011)

Efficacy and safety of oral metronomic etoposide in adult patients with metastatic osteosarcoma
por: Perret, Audrey, et al.
Publicado: (2020)

Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma
por: Ghiaseddin, Ashley, et al.
Publicado: (2017)

EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma
por: Miao, Hongsheng, et al.
Publicado: (2014)

Metronomic combination chemotherapy using everolimus and etoposide for the treatment of non‐Hodgkin lymphoma
por: Wu, Ke, et al.
Publicado: (2019)

Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide.
por: de Jong, R. S., et al.
Publicado: (1997)

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer
por: van der Burg, M E L, et al.
Publicado: (2002)

MRP3: a molecular target for human glioblastoma multiforme immunotherapy.
por: Kuan, Chien-Tsun, et al.
Publicado: (2010)

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas
por: Killela, Patrick J., et al.
Publicado: (2014)

Hydroxymethanesulfonate from Volcanic Sulfur Dioxide: A “Mineral” Reservoir for Formaldehyde and Other Simple Carbohydrates in Prebiotic Chemistry
por: Kawai, J., et al.
Publicado: (2019)

Conversion of the prodrug etoposide phosphate to etoposide in gastric juice and bile.
por: de Jong, R. S., et al.
Publicado: (1997)

Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
por: Pujade-Lauraine, Eric
Publicado: (2013)

IMMU-27. ANALYSIS OF IMMUNE SIGNATURES IN PEDIATRIC GLIOBLASTOMAS FOR PATIENT STRATIFICATION TO IMMUNOTHERAPY
por: Chandramohan, Vidyalakshmi, et al.
Publicado: (2020)

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy
por: Gromeier, Matthias, et al.
Publicado: (2021)

Antitumor efficacy of D2C7-(scdsFv)-PE38KDEL, a novel immunotoxin targeting EGFRwt and EGFRvIII, by convection-enhanced delivery in orthotopic brain tumor mouse models
por: Bao, Xuhui, et al.
Publicado: (2013)

Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev)
por: Pastina, Pierpaolo, et al.
Publicado: (2017)

Monitoring Radiographic Brain Tumor Progression
por: Mehta, Ankit I., et al.
Publicado: (2011)

Everolimus and Bevacizumab in the Management of Recurrent, Progressive Intracranial NF2 Mutated Meningioma
por: Mathew Thomas, Vinay, et al.
Publicado: (2019)

The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma
por: Diplas, Bill H., et al.
Publicado: (2018)

Multiple phenotypic changes in mice after knockout of the B3gnt5 gene, encoding Lc3 synthase--a key enzyme in lacto-neolacto ganglioside synthesis
por: Kuan, Chien-Tsun, et al.
Publicado: (2010)

Metronomic cyclophosphamide with bevacizumab provides disease stabilization in patients with advanced uterine cancer
por: Alagkiozidis, Ioannis, et al.
Publicado: (2015)

Structured Annual Faculty Review Program Accelerates Professional Development and Promotion: Long-Term Experience of the Duke University Medical Center’s Pathology Department
por: Robboy, Stanley J., et al.
Publicado: (2017)

Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas
por: Zhang, Liwei, et al.
Publicado: (2014)

Treatment of paediatric pontine glioma with oral trophosphamide and etoposide
por: Wolff, J E A, et al.
Publicado: (2002)

Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
por: Koumarianou, Anna, et al.
Publicado: (2012)

Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin
por: Meczes, E L, et al.
Publicado: (2002)

Imaging of Convection Enhanced Delivery of Toxins in Humans
por: Mehta, Ankit I., et al.
Publicado: (2011)

Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma
por: Cham, K K Y, et al.
Publicado: (2010)

Deviating from IDSA treatment guidelines for non-purulent skin infections increases the risk of treatment failure in emergency department patients
por: Haran, J. P., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nnpsjjgojik94jnqb3lress8b6